MENU
+Compare
ARVN
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$7.55
Change
-$0.25 (-3.21%)
Capitalization
551.45M

ARVN Arvinas Forecast, Technical & Fundamental Analysis

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins... Show more

Industry: #Biotechnology
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ARVN with price predictions
Jun 27, 2025

Momentum Indicator for ARVN turns negative, indicating new downward trend

ARVN saw its Momentum Indicator move below the 0 level on June 27, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 85 similar instances where the indicator turned negative. In of the 85 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ARVN broke above its upper Bollinger Band on May 28, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

ARVN moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ARVN crossed bullishly above the 50-day moving average on June 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 163 cases where ARVN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.834) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). ARVN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (1.274) is also within normal values, averaging (252.247).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ARVN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARVN is expected to report earnings to fall 182.04% to -93 cents per share on July 31

Arvinas ARVN Stock Earnings Reports
Q2'25
Est.
$-0.94
Q1'25
Beat
by $2.14
Q4'24
Beat
by $0.33
Q3'24
Beat
by $0.16
Q2'24
Beat
by $0.59
The last earnings report on May 01 showed earnings per share of $1.14, beating the estimate of -100 cents. With 2.93M shares outstanding, the current market capitalization sits at 551.45M.
A.I. Advisor
published General Information

General Information

a developer of therapies to degrade disease-causing proteins

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
395 Winchester Avenue
Phone
+1 203 535-1456
Employees
445
Web
https://www.arvinas.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FMIHX15.300.10
+0.66%
FMI Large Cap Investor
CSXAX51.510.30
+0.59%
Calvert US Large Cap Core Rspnb Idx A
BUFSX14.510.08
+0.55%
Buffalo Small Cap Growth
NSFOX11.550.06
+0.52%
Natixis Target Retirement 2065 N
BSCRX16.69-0.03
-0.18%
Brandes Small Cap Value R6

ARVN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with ATXS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARVN
1D Price
Change %
ARVN100%
-3.14%
ATXS - ARVN
39%
Loosely correlated
N/A
ERAS - ARVN
39%
Loosely correlated
N/A
GMAB - ARVN
38%
Loosely correlated
-1.11%
TECH - ARVN
37%
Loosely correlated
-1.82%
CRGX - ARVN
36%
Loosely correlated
-0.71%
More